FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Matthias Bräutigam

Research Profile

Procedures

Concepts & Ideas

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
M Hofmann; T A Luger; Michael Meurer; R Salgo; Roland Aschoff; Matthias Bräutigam; Diamant Thaci
Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy.
Karsten Weller; N Schoepke; E Ardelean; Matthias Bräutigam; K Krause; Marcus Maurer
Selected urticaria patients benefit from a referral to tertiary care centres--results of an expert survey.
Karsten Weller; Torsten Zuberbier; Matthias Bräutigam; K Krause; Frank Siebenhaar; K Viehmann; Marcus Maurer
Management of chronic spontaneous urticaria in real life--in accordance with the guidelines? A cross-sectional physician-based survey study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Matthias Bräutigam (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: M Hofmann; T A Luger; Michael Meurer; R Salgo; Roland Aschoff; Matthias Bräutigam; Diamant Thaci
Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy.
Archives of dermatological research 2013;305(3):215-21.
2013: Karsten Weller; N Schoepke; E Ardelean; Matthias Bräutigam; K Krause; Marcus Maurer
Selected urticaria patients benefit from a referral to tertiary care centres--results of an expert survey.
Journal of the European Academy of Dermatology and Venereology : JEADV 2013;27(1):e8-16.
2013: Karsten Weller; Torsten Zuberbier; Matthias Bräutigam; K Krause; Frank Siebenhaar; K Viehmann; Marcus Maurer
Management of chronic spontaneous urticaria in real life--in accordance with the guidelines? A cross-sectional physician-based survey study.
Journal of the European Academy of Dermatology and Venereology : JEADV 2013;27(1):43-50.
2011: Jens-Michael Jensen; Josef G Meingassner; Andreas Scherer; Thomas Schwarz; Anton Stütz; Kerstin Ahrens; Matthias Bräutigam; Regina Fölster-Holst; Regine Gläser; Jürgen Harder; Ehrhardt Proksch
Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids.
Experimental dermatology 2011;20(10):783-8.
2011: Marcus Maurer; Martin Mempel; Michael Meurer; Kristian Reich; Franziska Ruëff; Knut Schäkel; Kaushik Sengupta; Stefan Seyfried; Christian Sieder; Jan C Simon; Sabine Altrichter; Thomas Bieber; Tilo Biedermann; Matthias Bräutigam; Randolf Brehler; Jürgen Grabbe; Nicolas Hunzelmann; Thilo Jakob; Andreas Jung; Jörg Kleine-Tebbe; Vera Mahler; Bettina Wedi; Torsten Zuberbier; Petra Staubach
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
The Journal of allergy and clinical immunology 2011;128(1):202-209.e5.
2009: Ehrhardt Proksch; Regina Fölster-Holst; Matthias Bräutigam; Marjan Sepehrmanesh; Stephan Pfeiffer; Jens-Michael Jensen
Role of the epidermal barrier in atopic dermatitis.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2009;7(10):899-910.
2009: Jens-Michael Jensen; Stephan Pfeiffer; Magdalena Witt; Matthias Bräutigam; Claudia Neumann; Michael Weichenthal; Thomas Schwarz; Regina Fölster-Holst; Ehrhardt Proksch
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis.
The Journal of allergy and clinical immunology 2009;124(3 Suppl 2):R19-28.
2009: Jens-Michael Jensen; Stephan Pfeiffer; Magdalena Witt; Matthias Bräutigam; Claudia Neumann; Michael Weichenthal; Thomas Schwarz; Regina Fölster-Holst; Ehrhardt Proksch
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis.
The Journal of allergy and clinical immunology 2009;123(5):1124-33.
2008: Thomas Schwarz; Inga Kreiselmaier; Thomas Bieber; Diamant Thaci; Jan C Simon; Michael Meurer; Thomas Werfel; Torsten Zuberbier; Thomas A Luger; Andreas Wollenberg; Matthias Bräutigam
A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis.
Journal of the American Academy of Dermatology 2008;59(1):34-40.
2008: Torsten Zuberbier; Matthias Bräutigam
Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease.
Journal of the European Academy of Dermatology and Venereology : JEADV 2008;22(6):718-21.
2007: Tilmann Oppel; Tatjana Pavicic; Stefanie Kamann; Matthias Bräutigam; Andreas Wollenberg
Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients.
Journal of the European Academy of Dermatology and Venereology : JEADV 2007;21(9):1175-80.
2007: Torsten Zuberbier; Lucie Heinzerling; Thomas Bieber; Uwe Schauer; Sven Klebs; Matthias Bräutigam
Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis.
Dermatology (Basel, Switzerland) 2007;215(4):325-30.
2005: Doris Staab; Roland Kaufmann; Matthias Bräutigam; Ulrich Wahn
Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2005;16(6):527-33.
2004: Roland Kaufmann; Regina Fölster-Holst; Peter Höger; Diamant Thaçi; Helena Löffler; Doris Staab; Matthias Bräutigam
Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants.
The Journal of allergy and clinical immunology 2004;114(5):1183-8.
2003: Christian Gessner; S Stenglein; Matthias Bräutigam; A Müller; Joachim Schauer
[Miflonide/Foradil via Aerolizer compared with other anti-inflammatory and anti-obstructive therapeutic regimens].
Pneumologie (Stuttgart, Germany) 2003;57(3):137-43.
2003: Rita Bunikowski; Martin Mielke; Matthias Bräutigam; Harald Renz; Ulrich Wahn
Effect of oral cyclosporin A in children with Staphylococcus aureus-colonized vs S aureus-infected severe atopic dermatitis.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2003;14(1):55-9.
2003: Ulrich Mrowietz; Stefan Wustlich; Godehart Hoexter; Michael Graeber; Matthias Bräutigam; Thomas Luger
An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion.
Acta dermato-venereologica 2003;83(5):351-3.
2002: Jutta Beier; Kai Michael Beeh; K Tröger; S Stenglein; Matthias Bräutigam; Roland Buhl; E W Schmidt
[Onset of action of formoterol in patients with moderate to severe, partially reversible airflow obstruction assessed by bodyplethysmography].
Pneumologie (Stuttgart, Germany) 2002;56(9):535-41.
2002: Diamant Thaçi; Matthias Bräutigam; Roland Kaufmann; Gottfried Weidinger; Carle Paul; Enno Christophers
Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.
Dermatology (Basel, Switzerland) 2002;205(4):383-8.
2002: Michael Meurer; Regina Fölster-Holst; Gottfried Wozel; Gottfried Weidinger; Michael Jünger; Matthias Bräutigam
Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study.
Dermatology (Basel, Switzerland) 2002;205(3):271-7.
2001: Rita Bunikowski; Kerstin Gerhold; Matthias Bräutigam; Eckard Hamelmann; Harald Renz; Ulrich Wahn
Effect of low-dose cyclosporin a microemulsion on disease severity, interleukin-6, interleukin-8 and tumor necrosis factor alpha production in severe pediatric atopic dermatitis.
International archives of allergy and immunology 2001;125(4):344-8.
2001: Hans Christian Korting; Hans-Jürgen Tietz; Matthias Bräutigam; Peter Mayser; G Rapatz; Carle Paul
One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. LAS-INT-06 Study Group.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2001;39(4):335-40.
2001: Rita Bunikowski; Doris Staab; F Kussebi; Matthias Bräutigam; G Weidinger; Harald Renz; Ulrich Wahn
Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2001;12(4):216-23.
2000: Wolfgang Czech; Matthias Bräutigam; G Weidinger; Erwin Schöpf
A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life.
Journal of the American Academy of Dermatology 2000;42(4):653-9.
1999: Henning Hamm; A Schwinn; Matthias Bräutigam; Gottfried Weidinger
Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. The Study Group.
The British journal of dermatology 1999;140(3):480-2.
1999: Rudolf E Schopf; O Hettler; Matthias Bräutigam; G Weidinger; U Kaben; Peter Mayser; V Resl
Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: a randomized, double-blind, multi-centre, 8-week clinical trial.
Mycoses 1999;42(5-6):415-20.
1998: Ulrich Mrowietz; Michael Graeber; Matthias Bräutigam; Mark Thurston; A Wagenaar; Gottfried Weidinger; Enno Christophers
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion.
The British journal of dermatology 1998;139(6):992-6.
1998: Rudolf E Schopf; T Hultsch; J Lotz; Matthias Bräutigam
Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A.
Journal of the European Academy of Dermatology and Venereology : JEADV 1998;11(3):234-9.
1998: Matthias Bräutigam; Gottfried Weidinger; S Nolting
Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits.
BMJ (Clinical research ed.) 1998;317(7165):1084.
1998: H Zachariae; B Abrams; S S Bleehen; Matthias Bräutigam; D Burrows; M J Ettelt; L Fry; R Happle; Uwe-Frithjof Haustein; J Ganslandt; E G Jung; J Knop; K H Kühne; B Mellein; N J Mørk; S Rogers; A G Schmidt; Rudolf E Schopf; M Sumner; K M Taube; Gottfried Weidinger; C Wurdel; E Zahn
Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
Dermatology (Basel, Switzerland) 1998;196(2):231-6.
1997: I Tausch; Matthias Bräutigam; Gottfried Weidinger; T C Jones
Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group.
The British journal of dermatology 1997;136(5):737-42.
1997: Hans Meffert; Matthias Bräutigam; L Färber; Gottfried Weidinger
Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
Acta dermato-venereologica 1997;77(2):137-41.
1996: MR Langenfeld; Matthias Bräutigam; Gottfried Weidinger; I Assmann; B Krönig; Roland E Schmieder
Antihypertensive efficacy and orthostatic tolerance of bunazosin vs nitrendipine: a multicentre double-blind randomized controlled study.
Journal of human hypertension 1996;10(12):831-6.
1996: Gustav Mahrle; HJ Schulze; Matthias Bräutigam; P Mischer; Rudolf E Schopf; E G Jung; Gottfried Weidinger; L Färber
Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study.
The British journal of dermatology 1996;135(5):752-7.
1996: Matthias Bräutigam; S Nolting; Rudolf E Schopf; Gottfried Weidinger
German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection.
The British journal of dermatology 1996;134 Suppl 46():18-21: discussion 38.
1995: Matthias Bräutigam; S Nolting; Rudolf E Schopf; Gottfried Weidinger
Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group.
BMJ (Clinical research ed.) 1995;311(7010):919-22.
1995: F Schatz; Matthias Bräutigam; E Dobrowolski; I Effendy; H Haberl; H Mensing; Gottfried Weidinger; A Stütz
Nail incorporation kinetics of terbinafine in onychomycosis patients.
Clinical and experimental dermatology 1995;20(5):377-83.
1995: H Hofmann; Matthias Bräutigam; Gottfried Weidinger; H Zaun
Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group.
Archives of dermatology 1995;131(8):919-22.
1995: E Haneke; I Tausch; Matthias Bräutigam; Gottfried Weidinger; D Welzel
Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group.
Journal of the American Academy of Dermatology 1995;32(1):72-7.
1994: Ernst G Jung; P J Haas; Matthias Bräutigam; Gottfried Weidinger
Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole.
Mycoses 1994;37(9-10):361-5.
1994: Alain Simon; I Merli; Muriel Del-Pino; Matthias Bräutigam; Dieter Welzel; K J Burger; Jaime Levenson
[Vasoselective, substance-specific actions of isradipine on the great arteries of hypertensives in comparison to metoprolol].
Arzneimittel-Forschung 1994;44(3):305-9.
1992: S Nolting; Matthias Bräutigam
Clinical relevance of the antibacterial activity of terbinafine: a contralateral comparison between 1% terbinafine cream and 0.1% gentamicin sulphate cream in pyoderma.
The British journal of dermatology 1992;126 Suppl 39():56-60.
1992: W Schulte; H Rüddel; Roland E Schmieder; Hartmut Schächinger; Matthias Bräutigam; Dieter Welzel
Pharmacological modulation of stress-induced cardiovascular hyperreactivity in essential hypertension.
Journal of cardiovascular pharmacology 1992;19 Suppl 3():S70-3.
1989: Dieter Welzel; Matthias Bräutigam
[Beta receptor block versus calcium antagonism. A comparative study of bopindolol and nifedipine with special regard to quality of life].
Arzneimittel-Forschung 1989;39(4):499-503.